Elisabet Størset1, Anders Åsberg, Morten Skauby, Michael Neely, Stein Bergan, Sara Bremer, Karsten Midtvedt. 1. 1 Department of Transplant Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway. 2 Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 3 School of Pharmacy, University of Oslo, Oslo, Norway. 4 Laboratory of Applied Pharmacokinetics, Children's Hospital Los Angeles, Los Angeles, CA. 5 Department of Pharmacology, Oslo University Hospital, Oslo, Norway. 6 Department of Medical Biochemistry, Oslo University Hospital, Oslo, Norway.
Abstract
BACKGROUND: Early after renal transplantation, it is often challenging to achieve and maintain tacrolimus concentrations within the target range. Computerized dose individualization using population pharmacokinetic models may be helpful. The objective of this study was to prospectively evaluate the target concentration achievement of tacrolimus using computerized dosing compared with conventional dosing performed by experienced transplant physicians. METHODS: A single-center, prospective study was conducted. Renal transplant recipients were randomized to receive either computerized or conventional tacrolimus dosing during the first 8 weeks after transplantation. The median proportion of tacrolimus trough concentrations within the target range was compared between the groups. Standard risk (target, 3-7 μg/L) and high-risk (8-12 μg/L) recipients were analyzed separately. RESULTS:Eighty renal transplant recipients were randomized, and 78 were included in the analysis (computerized dosing (n = 39): 32 standard risk/7 high-risk, conventional dosing (n = 39): 35 standard risk/4 high-risk). A total of 1711 tacrolimus whole blood concentrations were evaluated. The proportion of concentrations per patient within the target range was significantly higher with computerized dosing than with conventional dosing, both in standard risk patients (medians, 90% [95% confidence interval {95% CI}, 84-95%] vs 78% [95% CI, 76-82%], respectively, P < 0.001) and in high-risk patients (medians, 77% [95% CI, 71-80%] vs 59% [95% CI, 40-74%], respectively, P = 0.04). CONCLUSIONS: Computerized dose individualization improves target concentration achievement of tacrolimusafter renal transplantation. The computer software is applicable as a clinical dosing tool to optimize tacrolimus exposure and may potentially improve long-term outcome.
RCT Entities:
BACKGROUND: Early after renal transplantation, it is often challenging to achieve and maintain tacrolimus concentrations within the target range. Computerized dose individualization using population pharmacokinetic models may be helpful. The objective of this study was to prospectively evaluate the target concentration achievement of tacrolimus using computerized dosing compared with conventional dosing performed by experienced transplant physicians. METHODS: A single-center, prospective study was conducted. Renal transplant recipients were randomized to receive either computerized or conventional tacrolimus dosing during the first 8 weeks after transplantation. The median proportion of tacrolimus trough concentrations within the target range was compared between the groups. Standard risk (target, 3-7 μg/L) and high-risk (8-12 μg/L) recipients were analyzed separately. RESULTS: Eighty renal transplant recipients were randomized, and 78 were included in the analysis (computerized dosing (n = 39): 32 standard risk/7 high-risk, conventional dosing (n = 39): 35 standard risk/4 high-risk). A total of 1711 tacrolimus whole blood concentrations were evaluated. The proportion of concentrations per patient within the target range was significantly higher with computerized dosing than with conventional dosing, both in standard risk patients (medians, 90% [95% confidence interval {95% CI}, 84-95%] vs 78% [95% CI, 76-82%], respectively, P < 0.001) and in high-risk patients (medians, 77% [95% CI, 71-80%] vs 59% [95% CI, 40-74%], respectively, P = 0.04). CONCLUSIONS: Computerized dose individualization improves target concentration achievement of tacrolimus after renal transplantation. The computer software is applicable as a clinical dosing tool to optimize tacrolimus exposure and may potentially improve long-term outcome.
Authors: Lennaert C P Borra; Joke I Roodnat; Judith A Kal; Ron A A Mathot; Willem Weimar; Teun van Gelder Journal: Nephrol Dial Transplant Date: 2010-02-26 Impact factor: 5.992
Authors: Elly M van Duijnhoven; Johannes M M Boots; Maarten H L Christiaans; Leo M L Stolk; Nasrullah A Undre; Johannes P van Hooff Journal: Transpl Int Date: 2003-06-24 Impact factor: 3.782
Authors: Pierre Wallemacq; Jean-Sebastien Goffinet; Susan O'Morchoe; Thomas Rosiere; Gregory T Maine; Myriam Labalette; Giuseppe Aimo; Diana Dickson; Ed Schmidt; Reinhard Schwinzer; Rainer W Schmid Journal: Ther Drug Monit Date: 2009-04 Impact factor: 3.681
Authors: D J A R Moes; J J Swen; S A S van der Bent; T van der Straaten; A Inderson; E Olofsen; H W Verspaget; H J Guchelaar; J den Hartigh; B van Hoek Journal: Eur J Clin Pharmacol Date: 2016-03-02 Impact factor: 2.953
Authors: David J Taber; Zemin Su; James N Fleming; John W McGillicuddy; Maria A Posadas-Salas; Frank A Treiber; Derek Dubay; Titte R Srinivas; Patrick D Mauldin; William P Moran; Prabhakar K Baliga Journal: Transplantation Date: 2017-12 Impact factor: 4.939
Authors: Franc Andreu; Helena Colom; Laure Elens; Teun van Gelder; Ronald H N van Schaik; Dennis A Hesselink; Oriol Bestard; Joan Torras; Josep M Cruzado; Josep M Grinyó; Nuria Lloberas Journal: Clin Pharmacokinet Date: 2017-08 Impact factor: 6.447